News
Eli Lilly's obesity drugs delivered 38% revenue growth in the second quarter; but its oral GLP-1 candidate fell short, ...
It’s no secret that obesity is becoming an epidemic in the United States. It’s estimated that by 2030, 50 percent of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback